secwatch.observer — SEC 8-K summary
======================================

Issuer:     Savara Inc (SVRA)
CIK:        0001160308
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-258629
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share
--------------------------------------------------------------------------------

- 23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
- Underwriters granted 30-day option to purchase up to an additional 4.6M shares.
- Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.
- Offering expected to close October 31, 2025, subject to customary conditions.
- Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/0001193125-25-258629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/d62228d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-258629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer